We are encouraged to see Sanofi's progress with its pipeline. While new product launches should make significant revenue contributions in the early part of the decade, we expect Sanofi to continue looking to contain operating costs in order to grow earnings in the face of weakening sales of some of its biggest products. We also expect the company to look to grow revenue through additional partnering deals and acquisitions.
We believe the current share price represents an attractive entry point for long-term investors and are upgrading the stock to Outperform. Emerging markets, contributions from new products, continued strong performance of the diabetes and generics segments should help drive results.
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
Zacks Investment Research
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
